The landscape of American drug policy appears to be entering a pivotal moment, one that may redefine how the nation approaches cannabis and potentially other controlled substances.

For more than fifty years, the federal classification system that shapes drug enforcement and research has remained largely unchanged. Now, growing political consensus and evolving public attitudes suggest that a major revision could be near. What was once an issue confined to the margins of policy debate has moved into the mainstream, reflecting a cultural and scientific shift in how the United States understands both the risks and the benefits of cannabis.

At the center of this potential transformation is the question of reclassification. Cannabis is currently listed as a Schedule I controlled substance under the federal Controlled Substances Act, a category reserved for drugs considered to have a high potential for abuse and no accepted medical use.